Firdausi Qadri

Summary

Affiliation: International Centre for Diarrhoeal Disease Research
Country: Bangladesh

Publications

  1. Bourque D, Bhuiyan T, Genereux D, Rashu R, Ellis C, Chowdhury F, et al. Analysis of the Human Mucosal Response to Cholera Reveals Sustained Activation of Innate Immune Signaling Pathways. Infect Immun. 2018;86: pubmed publisher
    ..These previously unidentified features of the innate immune response to V. cholerae extend our understanding of the mucosal immune signaling pathways and effectors activated in vivo following cholera. ..
  2. Dorman M, Domman D, Uddin M, Sharmin S, Afrad M, Begum Y, et al. High quality reference genomes for toxigenic and non-toxigenic Vibrio cholerae serogroup O139. Sci Rep. 2019;9:5865 pubmed publisher
    ..cholerae in the future. These genomes also offer new insights into the biology of a V. cholerae serogroup that, from a genomic perspective, is poorly understood. ..
  3. Khan A, Islam M, Islam M, Ahmed A, Chowdhury M, Chowdhury F, et al. Oral cholera vaccination strategy: Self-administration of the second dose in urban Dhaka, Bangladesh. Vaccine. 2019;37:827-832 pubmed publisher
    ..This simplified, self-administered delivery strategy provides an ideal alternative for second-dose OCV delivery in hard-to-reach populations and resource-poor settings. ..
  4. Rashu R, Bhuiyan T, Hoq M, Hossain L, Paul A, Khan A, et al. Cognate T and B cell interaction and association of follicular helper T cells with B cell responses in Vibrio cholerae O1 infected Bangladeshi adults. Microbes Infect. 2018;: pubmed publisher
    ..These studies were conducted on circulating Tfh cells; future studies will be directed at examining role of Tfh cells during cholera directly in gut mucosa of biopsied samples, at the single cell level if feasible. ..
  5. Ahmad S, Raqib R, Qadri F, Stephensen C. The effect of newborn vitamin A supplementation on infant immune functions: trial design, interventions, and baseline data. Contemp Clin Trials. 2014;39:269-79 pubmed publisher
    ..Connecting different aspects of immunological data in early infancy will help elucidate immune competence for protecting infection. Trial registration ClinicalTrials.gov: NCT01583972. ..
  6. Uddin M, Wahed T, Saha N, Kaukab S, Khan I, Khan A, et al. Coverage and acceptability of cholera vaccine among high-risk population of urban Dhaka, Bangladesh. Vaccine. 2014;32:5690-5 pubmed publisher
    ..To improve the coverage of the cholera vaccine, exploration of effective solutions to reach the unvaccinated population is required. The vaccine may be more acceptable to the community through changing its taste. ..
  7. Qadri F, Ali M, Chowdhury F, Khan A, Saha A, Khan I, et al. Feasibility and effectiveness of oral cholera vaccine in an urban endemic setting in Bangladesh: a cluster randomised open-label trial. Lancet. 2015;386:1362-1371 pubmed publisher
    ..Bill & Melinda Gates Foundation. ..
  8. Chowdhury F, Kuchta A, Khan A, Faruque A, Calderwood S, Ryan E, et al. The increased severity in patients presenting to hospital with diarrhea in Dhaka, Bangladesh since the emergence of the hybrid strain of Vibrio cholerae O1 is not unique to cholera patients. Int J Infect Dis. 2015;40:9-14 pubmed publisher
    ..As a shift in severity for both cholera and non-cholera was observed, these results indicate that the altered El Tor strain cannot fully explain the difference in cholera severity before and after 2001. ..
  9. Sarker A, Islam Z, Khan I, Saha A, Chowdhury F, Khan A, et al. Estimating the cost of cholera-vaccine delivery from the societal point of view: A case of introduction of cholera vaccine in Bangladesh. Vaccine. 2015;33:4916-21 pubmed publisher
    ..98. The purchase cost of the vaccine accounted for 58% of the overall cost of vaccination. Attempts to reduce the per-dose cost of the vaccine are likely to have a large impact on the cost of similar vaccination campaigns in the future. ..

More Information

Publications26

  1. Qadri F, Asaduzzaman M, Wenneras C, Mohi G, Albert M, Abdus Salam M, et al. Enterotoxin-specific immunoglobulin E responses in humans after infection or vaccination with diarrhea-causing enteropathogens. Infect Immun. 2000;68:6077-81 pubmed
  2. Qadri F, Ahmed F, Ahmed T, Svennerholm A. Homologous and cross-reactive immune responses to enterotoxigenic Escherichia coli colonization factors in Bangladeshi children. Infect Immun. 2006;74:4512-8 pubmed
  3. Qadri F, Bhuiyan T, Sack D, Svennerholm A. Immune responses and protection in children in developing countries induced by oral vaccines. Vaccine. 2013;31:452-60 pubmed publisher
  4. Khan A, Chowdhury F, Leung D, LaRocque R, Harris J, Ryan E, et al. Cholera in pregnancy: Clinical and immunological aspects. Int J Infect Dis. 2015;39:20-4 pubmed publisher
    ..These findings suggest that the evaluation of safety and immunogenicity of oral cholera vaccines in pregnancy should be an area of future investigations. ..
  5. Qadri F, Ali M, Lynch J, Chowdhury F, Khan A, Wierzba T, et al. Efficacy of a single-dose regimen of inactivated whole-cell oral cholera vaccine: results from 2 years of follow-up of a randomised trial. Lancet Infect Dis. 2018;18:666-674 pubmed publisher
    ..The absence of protection of young children might reflect a lesser degree of pre-existing natural immunity in this age group. Bill & Melinda Gates Foundation to the International Vaccine Institute. ..
  6. Bhuiyan T, Hoq M, Nishat N, Al Mahbuba D, Rashu R, Islam K, et al. Enumeration of Gut-Homing β7-Positive, Pathogen-Specific Antibody-Secreting Cells in Whole Blood from Enterotoxigenic Escherichia coli- and Vibrio cholerae-Infected Patients, Determined Using an Enzyme-Linked Immunosorbent Spot Assay Technique. Clin Vaccine Immunol. 2016;23:27-36 pubmed publisher
  7. Qadri F, Bhuiyan T, Dutta K, Raqib R, Alam M, Alam N, et al. Acute dehydrating disease caused by Vibrio cholerae serogroups O1 and O139 induce increases in innate cells and inflammatory mediators at the mucosal surface of the gut. Gut. 2004;53:62-9 pubmed
    ..These cells and factors of the innate arm may be important in the host's defence against cholera. Such effects may need to be simulated in a vaccine to achieve long lasting protection from cholera. ..
  8. request reprint
    Qadri F, Ahmed T, Ahmed F, Bradley Sack R, Sack D, Svennerholm A. Safety and immunogenicity of an oral, inactivated enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine in Bangladeshi children 18-36 months of age. Vaccine. 2003;21:2394-403 pubmed
    ..003 to <0.001). This study thus shows that the CF-BS-ETEC vaccine is well tolerated in children, 18-36 months of age and gives rise to significant systemic and mucosal IgA antibody responses. ..
  9. request reprint
    Qadri F, Chowdhury M, Faruque S, Salam M, Ahmed T, Begum Y, et al. Peru-15, a live attenuated oral cholera vaccine, is safe and immunogenic in Bangladeshi toddlers and infants. Vaccine. 2007;25:231-8 pubmed
    ..The responses to the reduced dose was lower. These studies demonstrate that Peru-15 at a dose of 2x10(8)cfu is safe and immunogenic in children in Bangladesh. ..
  10. request reprint
    Qadri F, Ahmed T, Ahmed F, Begum Y, Sack D, Svennerholm A. Reduced doses of oral killed enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine is safe and immunogenic in Bangladeshi infants 6-17 months of age: dosing studies in different age groups. Vaccine. 2006;24:1726-33 pubmed
    ..05-0.001). This study thus demonstrates that reduced doses of the ETEC vaccine is immunogenic in children and infants as well as safe in infants down to 6 months of age. ..
  11. Saha A, Khan A, Salma U, Jahan N, Bhuiyan T, Chowdhury F, et al. The oral cholera vaccine Shancholâ„¢ when stored at elevated temperatures maintains the safety and immunogenicity profile in Bangladeshi participants. Vaccine. 2016;34:1551-1558 pubmed publisher
    ..Bill & Melinda Gates Foundation. Clinical Trials.gov number NCT01762930. ..
  12. Khan I, Sayeed M, Sultana N, Islam K, Amin J, Faruk M, et al. Development of a Simple, Peripheral-Blood-Based Lateral-Flow Dipstick Assay for Accurate Detection of Patients with Enteric Fever. Clin Vaccine Immunol. 2016;23:403-409 pubmed publisher
    ..These results suggest that this dipstick assay can be very useful for the detection of enteric fever patients especially in regions of endemicity. ..
  13. request reprint
    Qadri F, Chowdhury M, Faruque S, Salam M, Ahmed T, Begum Y, et al. Randomized, controlled study of the safety and immunogenicity of Peru-15, a live attenuated oral vaccine candidate for cholera, in adult volunteers in Bangladesh. J Infect Dis. 2005;192:573-9 pubmed
    ..A lower immunological response against cholera toxin B subunit was detected.CONCLUSIONS. The safety and immunogenicity of this Peru-15 vaccine candidate indicates the usefulness of future studies in Bangladesh, where cholera is endemic. ..
  14. Qadri F, Saha A, Ahmed T, Al Tarique A, Begum Y, Svennerholm A. Disease burden due to enterotoxigenic Escherichia coli in the first 2 years of life in an urban community in Bangladesh. Infect Immun. 2007;75:3961-8 pubmed
    ..032 to 0.023). Children with ETEC diarrhea were underweight and growth stunted at the 2-year follow-up period, showing the importance of strategies to prevent and decrease ETEC diarrheal morbidity in children...
  15. Qadri F, Svennerholm A, Shamsuzzaman S, Bhuiyan T, Harris J, Ghosh A, et al. Reduction in capsular content and enhanced bacterial susceptibility to serum killing of Vibrio cholerae O139 associated with the 2002 cholera epidemic in Bangladesh. Infect Immun. 2005;73:6577-83 pubmed
    ..cholerae O139. Consequently, this assay may be useful in studies of both O139-infected patients and recipients of O139 vaccines...
  16. Khan A, Ali M, Chowdhury F, Saha A, Khan I, Khan A, et al. Safety of the oral cholera vaccine in pregnancy: Retrospective findings from a subgroup following mass vaccination campaign in Dhaka, Bangladesh. Vaccine. 2017;35:1538-1543 pubmed publisher
    ..OR (95% CI): 0.45 (0.11-1.88). No excess of adverse fetal outcomes associated with receipt of OCV was observed in this study. Clinical Trials.gov number NCT01339845. ..
  17. Qadri F, Ryan E, Faruque A, Ahmed F, Khan A, Islam M, et al. Antigen-specific immunoglobulin A antibodies secreted from circulating B cells are an effective marker for recent local immune responses in patients with cholera: comparison to antibody-secreting cell responses and other immunological markers. Infect Immun. 2003;71:4808-14 pubmed